RM Douglas EB Chalker B Treacy
DOI:10.1002/14651858.CD000980
Add feedback to this review/protocol
Plasma vitamin C level in healthy persons is saturated with doses less than 0.5 g/day (Levine et al. JAMA 1999;281:1415-23). Consequently, there is no basis to assume that doses substantially higher than 1 g/day would affect the incidence of colds when considering the negative findings of the large-scale trials (mostly 1 g/day). On the other hand, common cold infections change vitamin C metabolism so that vitamin C levels in leucocytes and in urine are reduced during colds (for review see Hemila: Br J Nutr 1992;67:3-16). Accordingly, it is quite possible that therapeutic supplementation during colds might show dose-dependency in the region above 1 g/day (Hemila: J Clin Epidemiol 1996;49:1079-87; Hemila: Med Hypotheses 1999;52:171-8). Nevertheless, our Cochrane review is limited to placebo-controlled trials, and in these trials the highest dose was "only" 6 g/day. There is such a great variability in the published trials so that comparing trials with different doses allows only hypothetical conclusions about dose-dependency. Furthermore, few of the trials examined therapeutic supplementation during common cold episodes, and those trials were mostly negative. Thus, the published trials do not give support nor do they dispute the possibility that therapeutic doses substantially higher than 1 g/day would be much more beneficial compared with 1 g/day.
Prof. Bob Douglas
Dr. Harri Hemilä
I certify that I have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of my criticisms.
Ludvigsson writes explicitly "Every class was divided at random into two groups." In our opinion this statement means that Ludvigsson was taking one class and he divided the subjects of that one class to two groups 'at random,' and then he went to another class and similarly randomized the second class. We disagree that cluster randomisation applied here.
As to the two small twin trials: Miller 1977 expicitly stated that "analysis of the paired comparisons?" so we conclude their SE values in their main table are based on paired t-test, event though this is not explicitly stated in their methods; Carr 1981 explicitly stated "the results for the six summary cold variables of the paired analyses of variance between active and placebo groups are shown?" so we conclude their P-values refer to paired analyses. In any case, the mean difference between the groups is the same whether we calculate difference of means or mean of paired differences. Failure to take into account the pairing of data would mean that we would be over-conservative in our estimate of the precision of any effect, but it is unlikely that this issue would anyway have influenced our conclusions in a meaningful way.
In the current review we have not used as an outcome variable mean symptom days per person but have concentrated on mean symptom days per episode.
In the new edition of the review we have avoided this problem described above by combining all trial arms that were compared with the one placebo group into one trial arm for purposes of the meta-alysis
Prof Bob Douglas
One gram daily is a small dose. Most mammals make 3 or more grams in their livers. Any practitioner of orthomolecular medicine knows that a minimum of several grams a day is needed to surely prevent a cold, and as much as 20 grams to cure one in progress. Not one trial in your RCT's qualifies.
Further to David Wooff's comment, I suspect there may be other statistical flaws in this review that could be placed under the heading, 'unit of analysis errors'.
At least one study (Lugviggson) appears to be a cluster randomized trial, yet there is no discussion of the possible over-weighting of this study when naively included in the meta-analyses.
At least two studies appear to be twin studies (Carr and Miller). Should the matching be taken into account in the analysis, in a similar way to a simple cross-over trial?
The particular meta-analysis for 'Mean symptom days per person' in the comparison 'Vitamin C 1G daily or more vs placebo' worries me considerably. Of the six studies (10 contributions) included in this analysis, I suspect that at most two are free of unit of analysis errors of various kinds. This makes it a wonderful teaching example, but for the wrong reasons.
There appear to be several instances where there is considerable overlap between studies, but they are treated as independent studies as far as the meta-analysis is concerned. For example, the Anderson 1974, 1974a, 1974b studies seem to be treated as independent in graph (comparison 01, outcome 04), but the control groups seem identical, and 275 people in the treatment group seem the same in each study. The effect is to inflate the value of this study. Indeed, the difference between the treatment groups for Anderson 1974a, 1974b (33 new people, *all* apparently with one or more respiratory episodes) raises further issues.
I have always heard that Vitamin C was good for preventing colds. I have always made sure that I take my daily dose of multivitamins that have 100% USRDA value of all the essentials. I have always had at least 1 cold, maybe 2 every year. But for the past 3 years, whenever I feel the little tickle in my throat that more often than not signals the onset of a cold, I will take a megadose of vitamin C (more than 1000%USRDA). That day, I will sneeze and have a sinus headache. However, the next morning, my symptoms will have cleared up and I will be cold-free.
P. Cruz
Date received: November 25, 2008
Cite this comment as: http://www.cochranefeedback.com/cf/cda/citation.do?id=9896#9896
I would be interested in your results if you restricted studies to those using 1.0 grams or more.
Thanks
Roger